封面
市場調查報告書
商品編碼
1218663

靜脈注射用鐵劑(IV鐵劑)的全球市場

Intravenous (IV) Iron Drugs

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 354 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

靜脈注射用鐵劑(IV鐵劑)的全球市場2030年前將達到48億美元

在COVID-19後改變的商務環境中,2022年27億美元預測的靜脈注射用鐵劑(IV鐵劑)的全球市場2030年前將達到48億美元的修正規模,在2022年~2030年分析期間預計將以7.4%的年複合成長率增長。本報告所分析之市場區隔之一的羧基麥芽糖鐵將記錄年複合成長率7.7%,到分析期間結束時將達到23億美元。考慮疫情後的復甦,聚葡萄糖鐵領域今後8年的年複合成長率將修正為6.7%。

美國市場估算為9億4,910萬美元,中國則將以年複合成長率10.8%增長

美國的靜脈注射用鐵劑(IV鐵劑)市場在2022年估算為9億4,910萬美元。作為世界第2大經濟大國的中國,在2022年~2030年複合成長率預計將為10.8%,2030年達到6億5,840萬美元的市場規模。其他熱門的地區市場有日本和加拿大,在2022年~2030年預計將各以5.2%和6.2%的速度成長。在歐洲市場中,德國預計將以年複合成長率約6.1%成長。澳洲,印度,韓國等國家的推動下亞太地區的市場2030年前將達到5億5,020萬美元。

調查對像企業範例

  • Allergan Plc.
  • AMAG Pharmaceuticals Inc.
  • American Regent Inc.
  • Luitpold Pharmaceuticals
  • Pharmacosmos A/S
  • Sanofi US
  • Vifor Fresenius Medical Care Renal Pharma
  • Vifor Pharma Ltd.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

第4章 競爭

簡介目錄
Product Code: MCP-6464

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Intravenous (IV) Iron Drugs Market to Reach $4.8 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Intravenous (IV) Iron Drugs estimated at US$2.7 Billion in the year 2022, is projected to reach a revised size of US$4.8 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2022-2030. Ferric Carboxymaltose, one of the segments analyzed in the report, is projected to record a 7.7% CAGR and reach US$2.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Iron Dextran segment is readjusted to a revised 6.7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $949.1 Million, While China is Forecast to Grow at 10.8% CAGR

The Intravenous (IV) Iron Drugs market in the U.S. is estimated at US$949.1 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$658.4 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.2% and 6.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$550.2 Million by the year 2030.

Select Competitors (Total 33 Featured):

  • Allergan Plc.
  • AMAG Pharmaceuticals Inc.
  • American Regent Inc.
  • Luitpold Pharmaceuticals
  • Pharmacosmos A/S
  • Sanofi US
  • Vifor Fresenius Medical Care Renal Pharma
  • Vifor Pharma Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Iron Deficiency Anemia (IDA) - A Major Global Health Concern
    • EXHIBIT 1: Iron Deficiency Prevalence by Disease: Analyzed by Percentage Number of Patients with ID and IDA in CKD (with dialysis), Non-Dialysis-CKD, Congestive Heart Failure, Chemotherapy Induced Anemia, Irritable Bowel Disease, Patient Blood Management (Surgery), Heavy Uterine Bleeding and Postpartum (OB-GYN)
    • Impact of Covid-19 and Global Economic Update
    • War & Inflation Supersede COVID-19 as Major Downside Risks for the Global Economy in 2023 & Beyond
    • Here's How Inflationary Pressures Affect the Economy
    • Russia-Ukraine War, the Primary Culprit Responsible for the Hardships
    • Stubbornly High Inflation to Single Handedly Drag Down Global Growth
    • Here's What's Causing the Current Spike in Inflation
    • EXHIBIT 2: War-Induced Commodity Price Increases & Broad Based Price Pressures Mark the Return of Global Inflation in 2022 to the Highest Level Seen Since 1996: Global Inflation Rates (In %) for the Years 2019 Through 2024
    • EXHIBIT 3: War, Global Inflation, Cost of Living Crisis, Failed Fiscal Policy Attempts to Restore Price Stability & Contain Downside Risks to Result in Sharper-Than-Expected Slowdown in Global Economic Growth: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020, 2021, 2022 and 2023
    • EXHIBIT 4: Recession Triggered by Uncontrolled Inflation or Unemployment, Which is the Greater Evil? Inflation Battling Policy Measures to Slowdown Post Pandemic Recovery in Unemployment Rates: Global Number of Unemployed People (In Million) for Years 2019 Through 2023
    • Competitive Landscape
    • EXHIBIT 5: Intravenous (IV) Iron Drugs - Global Key Competitors Percentage Market Share in 2023 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 33 Players Worldwide in 2023 (E)
    • Global Market Overview and Prospects
    • Global Intravenous Iron Drugs Market Driven by Rising Incidence of CKD and Cancer
    • Ferric Carboxy Maltose Dominates the Global Intravenous Iron Drugs Market
    • CKD Leads the Application Segment, Cancer Expected to Witness Fastest Growth
    • North America and Europe Hold Major Share, Asia-Pacific Witnesses Rapid Growth
    • Low- and Mid-income Countries Present Lucrative Penetration Opportunities for IV Iron Drugs
    • The Target Patient Population
    • Leading Intravenous Iron Drugs Globally
    • Leading IV Iron Drugs Available in the Market
    • Leading Intravenous Iron Drugs: In a Nutshell
    • Ferinject/Injectafer - The Leading Intravenous Iron Drug Globally
    • EXHIBIT 6: Worldwide Ferinject (Injectafer) Sales (in US$ Million): 2018-2022E
    • Venofer®
    • EXHIBIT 7: Worldwide Venofer Sales (in US$ Million): 2018-2022E
    • Feraheme
    • EXHIBIT 8: Worldwide Feraheme Sales (in US$ Million): 2018-2022E
    • Gluconate (Ferrlecit® and Nulecit)
    • Dextran
    • Monoferric
    • Triferic AVNU
    • INFeD
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Expanding Pool of ESRD and CKD Patients - The Major Growth Driver for Intravenous (Iv) Iron Drugs
    • EXHIBIT 9: ESRD Prevalence Worldwide: Number of Treated ESRD Patients Per Million Population in Select Countries for 2019
    • EXHIBIT 10: Global Population of Kidney Disease Patients Undergoing Treatment by Type of Modality (2019 and 2022P): Percentage Breakdown of Patients Undergoing Dialysis Therapy and Kidney Transplantation
    • Dialysis Patients - A Major Market for Intravenous Iron Supplements
    • EXHIBIT 11: Global Dialysis Patient Population Breakdown by Geographic Region/Country (2019 and 2024)
    • EXHIBIT 12: Global Dialysis Patient Population Distribution by Modality for Select Countries (2016): Percentage Breakdown of Hemodialysis (HD) and Peritoneal Dialysis (PD) Patients
    • Ageing Population Drives Demand for IV Iron Drugs
    • EXHIBIT 13: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • EXHIBIT 14: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Rising Incidence of Cancer and the Associated Anemia Drives the Demand for Intravenous Iron Drugs
    • EXHIBIT 15: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • EXHIBIT 16: Breakdown of Total Number of Cancer Cases by Region: 2020
    • EXHIBIT 17: Breakdown of Total Number of Cancer Cases by Type: 2020
    • Rising Incidence of Diabetes to Propel the Market for Intravenous Iron Drugs
    • EXHIBIT 18: World Diabetes and Population Statistics (2019, 2030 & 2045)
    • EXHIBIT 19: Global Prevalence of Diabetes: Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2019, 2030, and 2045
    • Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market
    • EXHIBIT 20: Healthcare Expenditure as a % of GDP by Region for 2019
    • Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs
    • Comparison of Ferrous Salts with IV Iron Therapy
    • 2020: Pharmacosmos Receives FDA Approval for Single Dose Infusion of Ferric Derisomaltose in IDA Patients
    • Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
    • New Study Demonstrates IV Iron to Improve Long-term Outcomes in Heart Failure Patients
    • EXHIBIT 21: Incidence of Heart Failure (In 000s) in the U.S. by Gender for the Year 2022
    • Correction of IDA in Pregnancy Signals Opportunities
    • Women's Health - A Key Growth Opportunity
    • Perioperative and Postoperative Anemia - A Niche Market Beckons
    • Adverse Reactions of IV Iron Preparations Raise Concerns
    • Dosing Limitations Plague IV Iron Market
    • Select Therapeutic Areas and the Required Iron Doses
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Intravenous (IV) Iron Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 4: World 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Ferric Carboxymaltose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Ferric Carboxymaltose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 7: World 16-Year Perspective for Ferric Carboxymaltose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Iron Dextran by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Iron Dextran by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 10: World 16-Year Perspective for Iron Dextran by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Iron Sucrose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Iron Sucrose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 13: World 16-Year Perspective for Iron Sucrose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 19: World 16-Year Perspective for Chronic Kidney Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 22: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 25: World 16-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • Market Analytics
    • TABLE 29: USA Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • JAPAN
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • CHINA
    • TABLE 47: China Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: China 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: China 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • EUROPE
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • Market Analytics
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • FRANCE
    • TABLE 62: France Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 64: France 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 67: France 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • GERMANY
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • TABLE 80: UK Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Intravenous (IV) Iron Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • Market Analytics
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • INDIA
    • TABLE 119: India Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 121: India 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 124: India 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030
  • AFRICA
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxymaltose, Iron Dextran, Iron Sucrose and Other Product Types for the Years 2014, 2023 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Cancer, Inflammatory Bowel Disease and Other Applications for the Years 2014, 2023 & 2030

IV. COMPETITION